dc.creator | Cosío, Borja G. | es |
dc.creator | Shafiek, Hanaa | es |
dc.creator | Toledo-Pons, Nuria | es |
dc.creator | Iglesias, Amanda | es |
dc.creator | Barceló, Margalida | es |
dc.creator | Represas-Represas, Cristina | es |
dc.creator | López-Campos Bodineau, José Luis | es |
dc.creator | Soler-Cataluña, Juan José | |
dc.date.accessioned | 2022-11-10T11:45:34Z | |
dc.date.available | 2022-11-10T11:45:34Z | |
dc.date.issued | 2021-06-03 | |
dc.identifier.citation | Cosío, B.G., Shafiek, H., Toledo-Pons, N., Iglesias, A., Barceló, M., Represas-Represas, C. y López-Campos Bodineau, J.L. (2021). Characterization of COPD admissions during the first COVID-19 outbreak. International Journal of Chronic Obstructive Pulmonary Disease, 16, 1549-1554. https://doi.org/10.2147/COPD.S312493. | |
dc.identifier.issn | 1178-2005(electrónico) | es |
dc.identifier.uri | https://hdl.handle.net/11441/139230 | |
dc.description.abstract | Purpose: Exacerbations of COPD (ECOPD) are a frequent cause of hospitalization that seemed to ameliorate during the COVID outbreak. We aimed to evaluate the clinical characteristics of COPD-related hospital admissions and mortality in relation to the presence of COVID-19. Patients and Methods: We conducted a case-control study of patients admitted in four teaching hospitals throughout Spain between March 15 and April 30, 2020. Hospital admis- sions of respiratory cause with and without PCR-proven SARS-CoV-2 infection in patients with COPD were evaluated. Baseline and episode-related clinical characteristics were ana- lyzed. Logistic regression analysis was performed to evaluate the risk for mortality. Results: During the study period, 2101 patients were admitted for respiratory worsening, 1200 (57.1%) with COVID-19. A total of 228 (10.8%) were admitted due to COPD worsening, of whom 52 (22.8%) tested positive for COVID-19. COPD patients with COVID-19, when compared to those without COVID-19, were more frequently males with better lung function (FEV1 postbronchodilator 71% vs 46% respectively, p<0.001) and had higher mortality (44.9% vs 13.6% respectively, p<0.001) despite similar age, comorbidities, total days of hospitalization and admission to intensive care unit. COVID-19 and eosinopenia were the strongest risk factors for mortality in the multivariate analysis in the overall COPD population. Inhaled corticosteroid use was not associated to mortality. Conclusion: Hospitalizations for ECOPD without COVID-19 were more frequent than COPD with COVID-19 during the first outbreak, but the latter were associated with higher mortality and low eosinophil counts that warrant further analysis. © 2021 Cosio et al. | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Dove Medical Press LDT | es |
dc.relation.ispartof | International Journal of Chronic Obstructive Pulmonary Disease, 16, 1549-1554. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | COPD exacerbation | es |
dc.subject | Hospitalization | es |
dc.subject | Inhaled corticosteroids | es |
dc.subject | Mortality | es |
dc.title | Characterization of COPD admissions during the first COVID-19 outbreak | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://pubmed.ncbi.nlm.nih.gov/34113088/ | es |
dc.identifier.doi | 10.2147/COPD.S312493 | es |
dc.journaltitle | International Journal of Chronic Obstructive Pulmonary Disease | es |
dc.publication.volumen | 16 | es |
dc.publication.initialPage | 1549 | es |
dc.publication.endPage | 1554 | es |
dc.contributor.funder | GlaxoSmithKline (GSK) | es |